Assay methods for detecting the presence or amount of VCAM-1 or calprotectin in a sample using fluorescence resonance energy transfer (FRET).

The present invention relates to a method for predicting the prognosis of ischemic disease using an AGE-RAGE-based biomarker. The biomarker can be used as an indicator factor of the clinical severity of ischemic disease, can maximize the efficiency of stem-cell treatment by determination of the optimal timing of the stem-cell treatment on the basis of changes in the biomarker according to the severity of ischemic disease, and can also be used as a useful indicator factor for verifying efficacy after the stem-cell treatment.

Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMD-H1 and/or PGAM1, as markers of true labor.

A method for measuring the presence of calprotectin (S100A8/A) heterodimer in a biological sample using a particle-enhanced turbidimetric immunoassay (PETIA) based on monoclonal antibodies. The method can be adapted on automated standard analyzers and provides a reliable clinical measurement of calprotectin in faecal samples and extracts. The method is comparable to commerical two-site sandwich ELISA. The disclosed method counters spontaneous agglutination caused by calcium ions and low-molecular weight calcium-binding S100 proteins as observed with conventional PETIAs. The method can be used for measuring the presence of human calprotectin in stool, urine, serum, plasma, synovial liquid and other body liquids. Metrological traceability and high commutability with conventional immunoassays (ELISA) has been shown despite of different measurement principles used.

The disclosure relates to a point-of-care test device for diagnosis and detection of bacterial infections and hidden septic processes in samples of bodily fluids of premature and newborns comprising a quantitative or semi-quantitative lateral flow immunoassay unit adapted for parallel detection of proteins of the S100 family and for several detection of increased amounts of S100A12 and calprotectin in blood, serum, plasma, and saliva.

An electrochemical biosensor for detection of a calprotectin antigen in a sample solution. The electrochemical biosensor includes a reference electrode, a counter electrode, and a working electrode. The working electrode includes a surface coated with an anti-calprotectin antibody that binds to the calprotectin antigen in the sample solution. The electrochemical biosensor detects the concentration of the calprotectin antigen in the sample solution based on a resistance change at the surface of the working electrode.

CPNE7 protein or a nucleotide encoding for CPNE7 protein, or compositions containing the CPNE7 or the nucleotide and their uses are disclosed. The protein, nucleotide, or composition is useful for preventing or treating fatty liver disease. The CPEN7 protein regulates the expression of the SREBF1 (SREBP1) gene or a gene encoding the same. The composition can be a pharmaceutical composition or a quasi-drug composition, a health functional food, or a dietary supplement, which is suitable for preventing or alleviating fatty liver disease.

The invention relates to a combination of biomarkers and their use in brain injury or mild traumatic brain injury (mTBI) detection. The invention also relates to methods of treating the individual diagnosed with a traumatic brain injury (TBI) or a mild traumatic brain injury (mTBI) using such biomarkers.

A method to predict a propensity of an individual to develop atopic dermatitis is disclosed. The method, which involves use of biological markers, can also be used to evaluate the efficacy of a composition to treat atopic dermatitis.

A method for measuring the presence of calprotectin (S100A8/A) heterodimer in a biological sample using a particle-enhanced turbidimetric immunoassay (PETIA) based on monoclonal antibodies. The method can be adapted on automated standard analyzers and provides a reliable clinical measurement of calprotectin in faecal samples and extracts. The method is comparable to commerical two-site sandwich ELISA. The disclosed method counters spontaneous agglutination caused by calcium ions and low-molecular weight calcium-binding S100 proteins as observed with conventional PETIAs. The method can be used for measuring the presence of human calprotectin in stool, urine, serum, plasma, synovial liquid and other body liquids. Metrological traceability and high commutability with conventional immunoassays (ELISA) has been shown despite of different measurement principles used.